3Rs in Quality control of vaccines for human use: opportunities and barriers
|
|
- Martin O’Neal’
- 6 years ago
- Views:
Transcription
1 3Rs in Quality control of vaccines for human use: opportunities and barriers Sylvie Uhlrich Sanofi Pasteur Asian congress 2016 Alternatives and Animal Use in the Life Sciences, Karatsu, Saga, JAPAN Nov 15-18, Rs Asian Congress
2 Presentation outline Animal use in vaccine quality control 3Rs history and principles 3Rs successes and barriers Overview of successes illustrated with few examples Regulatory & scientific barriers Perspectives for the future International collaboration Consistency approach 3Rs Asian Congress
3 Animal use in vaccine quality control 3Rs Asian Congress
4 Short history of animals in vaccine research and testing Vaccine quality control tests have their roots in the work of 19th century scientists (Pasteur, Koch, Behring, Ehrlich, ) Test design (multi-dilution assay, use of reference preparation, ED50) were introduced in the 30s-50s of previous century (Prigge) Current quality in vivo control tests for established vaccines have been developed in the 50s -70s of the previous century (Kendrick test, NIH, etc) Sharp increase in animal numbers for vaccine quality control since 50s 3Rs Asian Congress
5 Current animal use for Vaccines Biologicals testing has the highest proportion of experiments causing severe pain and distress to animals out of various types of experiments (basic research, toxicity testing, etc.) Use in Vaccine industry Vaccine development (Research, non clinical evaluation of safety & efficacy) Production Batch control testing (safety and potency testing) Vaccines batch control testing is responsible for ~90% of animal use at vaccines manufacturers Batch control testing by manufacturers Batch control by National Control Laboratories 3Rs Asian Congress 2016
6 3Rs history and principles 3Rs Asian Congress
7 Why changing? Animal welfare Animals are sentient beings Large number of animals used for vaccine QC Large % of animals used in vaccine QC exposed to severe pain & distress Societal concern using animals Science In vivo models act as a black box Relevance to human sometimes questionable Lack of robustness, many factors may affect outcome High variability Economics In vivo tests are time consuming and human resource demanding In vivo tests are expensive Long cycle times Variability can lead to rejection of safe and efficacious vaccines, delays to market release & vaccine shortages 3Rs Asian Congress
8 Regulatory context No global harmonized framework: Many worlds A vaccine may be registered in more than 100 countries for which there are different release requirements The same product lot may be used to supply multiple markets Requirement to apply various in vivo methods for one product: Supply chain, testing and regulatory complexity More animals used per batch release e.g. 4 repeat testings at manufacturer & NCLs Increased costs & timelines Long cycle time & high variability Risk of vaccine shortage Example: Diphtheria potency Lethal challenge on GP Multi-dilution assay (ED50) Ph. Eur; WHO; JP; ChPh One-dilution assay (limit) Ph. Eur; WHO Seroneutralisation (limit) US PHS Immunogenicity assay ELISA or VERO cell assay on GP sera Ph. Eur ELISA or VERO cell assay on Mice sera CHPh = 7 different methods! 3Rs Asian Congress
9 The concept of 3Rs in vaccine research and testing Replacement Reduction Refinement Methods which avoid or replace the use of animals Methods which minimise the number of animals per experiment Methods which minimise suffering and improve animal welfare The principles of Humane Experimental Technique (1959) William Russel Rex Burch IABS conference at the zoological Gardens, London, 1985) 3Rs Asian Congress
10 Legal basis in Europe EMA/CPMP/SWP/728/95 (adopted 1997): Replacement of animal studies by in vitro models Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the 66 Community code relating to medicinal products for human use (Consolidated version: 67 05/10/2009); 68 Directive 2010/63/EU on the protection of animals used for scientific purposes on 3 June European Directive 2010/63/EU on the protection of animal used for scientific purpose Member States shall ensure that, wherever possible, a scientifically satisfactory method or testing strategy, not entailing the use of live animals, shall be used Sanofi policy: As a key element of Corporate Social Responsibility, Sanofi commits to meet or exceed regulations and standards for the use of animals and to develop alternative approaches. Sanofi fully adheres to the 3Rs 3Rs Asian Congress
11 3Rs successes and barriers 3Rs Asian Congress
12 Where do we stand now (1/2) (*) Partial implementation depending on product & market Possible use of alternative methods Ph. Eur. Status at SP All vaccines Allow omission of abnormal toxicity test / general safety test Toxicity test for Diphtheria Toxoids Allow the use of VERO cell based method at DS Remove the test at DP Toxicity test for Pertussis toxoid Allow CHO cell-based assay to replace HIST : at DS At DP stage Neurovirulence Test Oral Polio Vaccine Allow switch from non human primate to transgenic mice IPV inactivation test Allow replacement of 1ry monkey kidney cells with L20B cell line Test for adventitious agents Removal of GP & embryonated eggs for cell bank testing Replace in vivo tests by broad molecular methods (HTS) On going General desc 01/ /2017 Partial* Partial* Partial* partial* Under devt Partial* On going Under devt 3Rs Asian Congress
13 Where do we stand now (2/2) (*) Partial implementation depending on product & market Possible use of alternative methods Ph. Eur. Status at SP Potency tests D and T Toxoids Allow using serology instead of lethal endpoints Allow introducing single-dilution assay Potency test for inactivated Polio Vaccine Allow in vitro test Potency test for inactivated Rabies Vaccine Allow in vitro test Potency test for inactivated Hepatitis A vaccine Allow in vitro test Potency test for inactivated Hepatitis B vaccine Allow in vitro test Partial* Partial* Partial* under devt 3Rs Asian Congress
14 Current Limitations to 3Rs implementation Regulatory hurdles Scientific hurdles Lack of harmonization of regulatory requirements Prudence of Health Authorities to accept deviations from established guidelines Complexicity of regulatory changes do not generate strong incentive to develop and implement alternatives to animal testing Inherent variability of in vivo assays In vivo assays not in line with ICH Q2(R1) validation requirements The attributes of the product will likely be assessed differently when changing from an in vivo to an in vitro method 1:1 comparaison challenging and not necessarily justified 3Rs Asian Congress
15 Scientific hurdles The test methods used for routine QC are intended to monitor production consistency and to ensure comparability of quality attributes between commercial batches and clinical batches Information provided by in vivo and in vitro methods will be different In Vivo assay Measure Complex functional response In Vitro assay Mimic specific elements of complex in vivo response Agreement between methods should not always be expected An existing in vivo method may be substituted by more than 1 in vitro method in order to control key qualitative and quantitative attributes measured by the existing test 3Rs Asian Congress
16 Perspectives for the future 3Rs Asian Congress
17 Time for change Test Replacement Test Substitution Based on the demonstration of the scientific relevance of new test Potency tests Safety tests Capability of new test to control key quality attributes and maintain link with batches found safe and efficacious through clinical studies or routine use In vitro test to detect differences relevant for production process In vitro method should be specific and at least as sensitive as in vivo assay Where possible, functional assay; if not possible, detection of parameter(s) reflecting mode of action of toxic component 3Rs Asian Congress
18 Time for change.. 1:1 replacement Integrated approach The consistency approach is a concept which includes the strict application of GMP rules and guidelines, process validation and in process and final product tests and is aimed at verifying if a manufacturing process produces final batches which are consistent with one that fulfils all the criteria of Quality, Safety and Efficacy as defined in the marketing authorization, ultimately resulting in replacement of routinely used in vivo tests. De Mattia et al, Biologicals 39:59-65, Rs Asian Congress
19 Conclusion 3Rs acceptability based on Full GMP implementation Reliable, standardized and validated process; in process monitoring Consistent product demonstrated safe & efficacious Relevant science Tests Validated according to ICH Q2(R1) Regulatory acceptance Easier for new vaccines For existing vaccines, need to facilitate post approval changes An understanding, recognition and implementation of the change by all stakeholders in a timely manner Need for a global harmonization endorsed by an International organization Involvement of all stakeholders (regulators, scientists, animal welfare organizations, the public and decision makers) in communication of best practices 3Rs Asian Congress
20 International collaborative efforts Human Rabies Vaccines (Potency test replacement) Harmonisation of 3Rs in Biologicals (deletion GST/ATT) HIST replacement international workshops & collaborative studies NIH ICVAM EDQM NC3Rs Vac2Vac project Vaccine batch to vaccine batch comparison by consistency testing 3Rs Asian Congress
21 VAC2VAC OVERVIEW The VAC2VAC project has received funding for 5 years from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement Nº Total project budget (March March 2022): 7.85M EU funding in cash 8.13M from EFPIA partners in kind 20 participants: 14 public partners, 6 EFPIA companies Objectives: Provide proof of concept of consistency approach for batch release testing of established vaccines using sets (toolbox) of in vitro and analytical methods Expected results: Enhance replacement, reduction or refinement of animal use (3Rs) Development, optimization and evaluation of in vitro analytical methods to be used in the consistency approach for vaccine quality control Demonstrate proof of concept of consistency approach for several types of established veterinary and human model vaccines With regulators define procedural guidance for regulatory approval and routine use 3Rs asian congress
22 VAC2VAC PARTNERS 22
23 Acknowledgements Sanofi Pasteur France Emmanuelle Coppens, Manager Analytical Excellence, Quality Control Nolwenn Nougarede, R&D 3R coordinator, Frédéric Moysan, Animal Welfare Officer Sanofi Pasteur Patrice Riou, Director Virology & Immunology platform, Analytical R&D, Europe Laurent Mallet, AVP, Head of Analytical Research & Development, Europe Sanofi Pasteur Canada Sue Nelson, Director, Analytical Expert 3Rs, Global Analytical Process & Technology 3Rs Asian Congress
24 Thank you 3Rs Asian Congress
The European Pharmacopoeia and the 3Rs
The European Pharmacopoeia and the 3Rs EU Expert Working Group on the information on the Three Rs Bruxelles, 29-30 November 2012 Emmanuelle Charton EDQM, European Pharmacopoeia Department Structure The
More informationInterested parties (organisations or individuals) that commented on the draft document as released for consultation.
9 November 2017 EMA/CHMP/CVMP/3Rs/83712/2017 Committee for Medicinal Products for Human Use (CHMP) Committee for Medicinal Products for Veterinary Use (CVMP) Overview of comments received on 'Guidance
More informationGuidance for individual laboratories for transfer of quality control methods validated in collaborative trials with a view to implementing 3Rs
9 November 2017 EMA/CHMP/CVMP/3Rs/94436/2014 Committee for Medicinal Products for Human Use (CHMP) Committee for Medicinal Products for Veterinary Use (CVMP) Guidance for individual laboratories for transfer
More informationReplacement of animal tests in the European Pharmacopoeia
EUROPEAN PHARMACOPOEIA: TACKLING FUTURE CHALLENGES OF THE QUALITY OF MEDICINES TOGETHER 27-28 September 2016, Tallinn, Estonia Replacement of animal tests in the European Pharmacopoeia Dr Karl-Heinz Buchheit
More informationNational Veterinary Assay Laboratory Ministry of Agriculture, Forestry and Fisheries
National Veterinary Assay Laboratory Ministry of Agriculture, Forestry and Fisheries VICH General Principles and Harmonization of Criteria to Waive TABST for Vaccines for veterinary Use 1 1. WHAT Is VICH?
More informationDealing with Post-market Issues: OOS Case Study
Dealing with Post-market Issues: OOS Case Study CASE STUDY: Potency Out of Specification Result ISSUE: 3 lots of DTwP-HB (diptheria-tetanus-whole cell pertussishepatitis B) combination vaccine failed the
More informationGuideline on the principles of regulatory acceptance of 3Rs (replacement, reduction, refinement) testing approaches
15 December 2016 EMA/CHMP/CVMP/JEG-3Rs/450091/2012 Committee for Medicinal Products for Human Use (CHMP) Committee for Medicinal Products for Veterinary Use (CVMP) Guideline on the principles of regulatory
More informationOverview of Biologics Testing and Evaluation: Regulatory Requirements and Expectations. Audrey Chang, PhD, Senior Director Development Services
Overview of Biologics Testing and Evaluation: Regulatory Requirements and Expectations Audrey Chang, PhD, Senior Director Development Services Definition of Biologics: PHS Act, section 351 Virus, therapeutic
More informationGuideline on requirements for the production and control of immunological veterinary medicinal products
14 June 2012 EMA/CVMP/IWP/206555/2010 Committee for Medicinal Products for Veterinary Use (CVMP) Guideline on requirements for the production and control of immunological veterinary Draft agreed by Immunologicals
More informationRabies Potency Testing
www.pei.de Rabies Potency Testing Regulatory Perspectives and Experiences in the Establishment of a Serological Assay Dr Constanze Goepfert Section Viral Vaccines Laboratory Head Das Paul-Ehrlich-Institut
More informationThe BSP148 project & the EDQM / BSP activities
Rabies NIH test replacement The BSP148 project & the EDQM / BSP activities Jean-Michel Chapsal DCVMN Regional Training Workshop Hyderabad - 09 May 2018 NIH Potency Test Developed by EB Seligmann Jr. and
More informationWAIVING THE TARGET ANIMAL BATCH SAFETY TEST AT MSD ANIMAL HEALTH. IABS Conference 2015
WAIVING THE TARGET ANIMAL BATCH SAFETY TEST AT MSD ANIMAL HEALTH IABS Conference 2015 MSD Animal Health One of the largest animal health companies in the world >400 different vaccines (food production
More informationHow the European Pharmacopoeia Provides the Framework to Implement QbD Principles
How the European Pharmacopoeia Provides the Framework to Implement QbD Principles Dr Emmanuelle Charton Deputy Head, European Pharmacopoeia Department, EDQM, Council of Europe Structure of the Presentation
More informationSetting Specifications for Biotech Products
Setting Specifications for Biotech Products Session 1: What to Control? Presentation by an EU Regulator Nanna Aaby Kruse, Senior Biological Assessor, member of BWP and BMWP WHAT TO CONTROL? Control of
More informationStandardisation of HIST and CHO Cell Assay for Residual Toxicity Testing of Acellular Pertussis Vaccines
Collaborative Study for the Standardisation of the Histamine Sensitizing Test in Mice and the CHO Cell-based Assay for the Residual Toxicity Testing of Acellular Pertussis Vaccines D. Xing, A. Maes, M.-E.
More informationReview of requirements for immunological medicinal products and their evolution since the start of Community legislation on medicines
www.pei.de Review of requirements for immunological medicinal products and their evolution since the start of Community legislation on medicines Dr. Carmen Jungbäck Paul-Ehrlich Institut, Germany London,
More informationQuality control of vaccines-a journey from classical approach to 3Rs.
Review Article http://www.alliedacademies.org/microbiology-current-research/ Quality control of vaccines-a journey from classical approach to 3Rs. Suresh Kumar 1*, Mahendra Pal Singh 1, Vijay K. Bharti
More informationElimination of target safety testing and the development of In-vitro assays for testing of livestock vaccines. by Dr G McKay and Dr R P Dempster
Elimination of target safety testing and the development of In-vitro assays for testing of livestock vaccines. by Dr G McKay and Dr R P Dempster Introduction Presentation Overview Introduction Regulatory
More informationThe European Pharmacopoeia
The European Pharmacopoeia Part 3 Gwenael Cirefice. 1 Agenda Latest news on Water for Injections monograph New General chapters in the field of biologicals (Host Cell Proteins, Raw materials for the production
More informationEuropean Guideline for Virus Safety Evaluation of Clinical Trial Material
Plasma Product Biotechnology Meeting, May 8 12, 2007 European Guideline for Virus Safety Evaluation of Clinical Trial Material Dr. Hannelore Willkommen Vice President Regulatory Affairs, NewLab Bioquality
More informationThe ethics of research involving animals
The ethics of research involving animals a guide to the Report Introduction Research involving animals has been the subject of intense debate in the UK and elsewhere. Too often this debate is presented
More informationAppropriate Control Strategies Eliminate the Need for Redundant Testing of Pharmaceutical Products
Date: April 23, 2012 Appropriate Control Strategies Eliminate the Need for Redundant Testing of Pharmaceutical Products Key Messages Importation quality control testing for pharmaceutical, biological/biotechnology
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BMWP/42832/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR
More informationAnimal Use in the Safety Evaluation of Chemicals: Harmonization and Emerging Needs
Animal Use in the Safety Evaluation of Chemicals: Harmonization and Emerging Needs Horst Spielmann Abstract An overview is provided of the legal framework in Europe for the use of experimental animals
More informationVariation Regulations (EU)
Variation Regulations (EU) Headlines of the Update APIC c view Hilde Vanneste APIC Task Force leader Hilde.Vanneste@its.jnj.com 1 Content Scope of regulation: Type of procedures and hence 2 strands Current
More informationFeedback from ECHA on dossier and substance evaluation
Feedback from ECHA on dossier and substance evaluation REACH Implementation Workshop X 13 December 2011 Wim De Coen ECHA Evaluation Unit I Overview Directorate of Evaluation Dossier evaluation Compliance
More informationAn Industry Perspective: The Complexity of Postapproval CMC Changes and Proposed Regulatory Strategies. SPEAKER: Suzanne Murray Biogen
An Industry Perspective: The Complexity of Postapproval CMC Changes and Proposed Regulatory Strategies SPEAKER: Suzanne Murray Biogen Contents 1. BioPhorum Operations Group (BPOG) and the Post-approvals
More informationCOMMUNICATION FROM THE COMMISSION. on the European Citizens' Initiative "Stop Vivisection"
EUROPEAN COMMISSION Brussels, 3.6.2015 C(2015) 3773 final COMMUNICATION FROM THE COMMISSION on the European Citizens' Initiative "Stop Vivisection" EN EN 1. INTRODUCTION "Stop Vivisection" is the third
More informationEuropean Regulations for Medicines Place and Role of the EDQM and the European Pharmacopoeia
European Regulations for Medicines Place and Role of the EDQM and the European Pharmacopoeia Cathie VIELLE Head of the Ph. Eur. Department, EDQM Structure Council of Europe, European Union and EDQM The
More informationSynopsis of Issues Concerning 9 CFR and VSM
Synopsis of Issues Concerning 9 CFR 113.8 and VSM 800.90 Kevin W. Ruby, M.S., Ph.D. Center for Veterinary Biologics Policy, Evaluation, and Licensing 1 Flow of Presentation Impetus Chronology of Potency
More informationStatutory Cost Regulation relating to vaccines for veterinary use
Statutory Cost Regulation relating to vaccines for veterinary use TierImpfStKostV 2010 Date of issue: 16 December 1996 Full title: "Statutory cost regulation relating to vaccines for veterinary use of
More informationEUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY. EudraLex. Volume 4
EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Ref. Ares(2015)4234460-12/10/2015 Medicinal products quality, safety and efficacy Brussels, 12 October 2015 EudraLex Volume 4 EU Guidelines
More informationAnnual statistical report for animals used in Ireland under scientific animal protection legislation
Annual statistical report for animals used in Ireland under scientific animal protection legislation - 2016 09 OCT 2017 Table of Contents 1 INTRODUCTION... 3 2 SUMMARY... 5 3 RESULTS... 6 3.1 Species and
More informationSanofi Pasteur India Pvt. Ltd., Mumbai
Sanofi Pasteur India Pvt. Ltd., Mumbai S. NO. Product Name Variation Approval date and letter num 1 VAXIGRIP Strain modification - SH 2014 12-68/96-DC(Pt-1) 2/3/2014 2 Pentaxim PFS with Notifiable change:
More informationTHE FUTURE OF IN VITRO SCREENING IN THE DEVELOPMENT OF NEW DRUGS. Hajime Kojima, JaCVAM, NIHS, Japan
THE FUTURE OF IN VITRO SCREENING IN THE DEVELOPMENT OF NEW DRUGS Hajime Kojima, JaCVAM, NIHS, Japan 1 3Rs of animal use (Russel and Burch 1959) Reduction (of animal use) Refinement (to lessen pain or distress
More informationACVM REGISTRATION STANDARD AND GUIDELINE FOR EFFICACY OF VACCINES
ISBN 0-478-07721-1 36 ACVM 07/04 New Zealand Food Safety Authority Post Office Box 2835 Wellington, New Zealand ACVM REGISTRATION STANDARD AND GUIDELINE FOR EFFICACY OF VACCINES This document may be altered
More informationNew Regulatory Paradigms For Biologicals & Vaccines - an industry perspective
New Regulatory Paradigms For Biologicals & Vaccines - an industry perspective ICDRA Pre-Meeting April 2, 2006 Elaine C. Esber, MD Chair, IFPMA Biologicals and Vaccines Committee Outline IFPMA - representing
More informationBiosimilar Monoclonal Antibodies: Registration Requirements. Henry M. J. Leng
Biosimilar Monoclonal Antibodies: Registration Requirements Henry M. J. Leng Disclaimer This presentation is given in my personal capacity and represents only the author s personal views and does not represent
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS NOTE FOR GUIDANCE 1 : DNA VACCINES NON-AMPLIFIABLE IN EUKARYOTIC CELLS FOR VETERINARY USE
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Veterinary Use CVMP/IWP/07/98-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS NOTE FOR GUIDANCE 1 : DNA VACCINES
More informationCOLLABORATIVE STUDY FOR THE ESTABLISHMENT OF
COLLABORATIVE STUDY FOR THE ESTABLISHMENT OF TWO EUROPEAN PHARMACOPOEIA BIOLOGICAL REFERENCE PREPARATIONS FOR CLOSTRIDIUM TETANI ANTISERUM FOR SEROLOGICAL POTENCY TESTING OF TETANUS VACCINES FOR VETERINARY
More informationDECISION TREE #1: ESTABLISHING ACCEPTANCE CRITERION FOR A SPECIFIED IMPURITY IN A NEW DRUG SUBSTANCE
DECISION TREE #1: ESTABLISHING ACCEPTANCE CRITERION FOR A SPECIFIED IMPURITY IN A NEW DRUG SUBSTANCE Determine impurity level in relevant batches 1 Determine mean + upper confidence limit for the impurity
More informationABPI response to European Commission consultation on advanced therapy medicinal products
ABPI response to European Commission consultation on advanced therapy medicinal products 28 March 2013 ABPI response to European Commission consultation on the regulation of advanced therapy medicinal
More informationGlobal Regulatory Perspective Workshop
Global Regulatory Perspective Workshop ISCT meeting Singapore 25 May 2016 Dr Nicolas FERRY ANSM, France Avertissement Lien d intérêt : personnel salarié de l ANSM (opérateur de l Etat). La présente intervention
More informationNon-clinical Assessment Requirements
Non-clinical Assessment Requirements Presented by: Maria Nieto-Gutierrez Safety and Efficacy of Medicines/Human Medicines Development and Evaluation An agency of the European Union Contents: Relevance
More informationRequirements for Yellow Fever Vaccine (Requirements for Biological Substances No. 3) Proposed Amendment
ENGLISH ONLY FINAL EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 13 to 17 October 2008 Requirements for Yellow Fever Vaccine (Requirements for Biological Substances No. 3) Proposed Amendment NOTE:
More informationDiscussion of comments GENERAL COMMENTS - OVERVIEW. Nigeria: The GLs are suitable and can be followed by the institute.
GL50-st4-comments OVERVIEW OF COMMENTS RECEIVED ON VICH GUIDELINE ON HARMONIZATION OF CRITERIA TO WAIVE TARGET ANIMAL BATCH SAFETY TESTING FOR INACTIVATED VACCINES FOR VETERINARY USE (GL50) Name of non-vich
More informationGuideline on the design of studies to evaluate the safety and efficacy of fish vaccines
14 November 2011 EMA/CVMP/IWP/314550/2010 Committee for Medicinal Products for Veterinary Use (CVMP) Guideline on the design of studies to evaluate the safety and efficacy of fish vaccines Draft agreed
More informationMethod Review by the Interagency Coordinating Committee for the Validation of Alternative Methods (ICCVAM)
Method Review by the Interagency Coordinating Committee for the Validation of Alternative Methods (ICCVAM) ICCVAM was created as an ad-hoc committee in 1994 and became a standing Committee in 2000. ICCVAM
More informationThe challenges of potency assay development for cell-based medicinal products in Europe
Focus Advanced therapies 5 The challenges of potency assay development for cell-based medicinal products in Europe Authors Valerie Pimpaneau, Senior Director, Voisin Consulting Life Sciences; François
More informationEuropean Regulatory Experiences and Expectations of HCP Analysis and Control
HCP Strategy Forum, Washington DC, January 26, 2015 www.pei.de European Regulatory Experiences and Expectations of HCP Analysis and Control Blood Products: Dr. Erika Friedl, PEI (DE) Discalimer: The views
More informationVaccines based on Recombinant Proteins and Adjuvant Systems: GSK's malaria vaccine candidate as a case study.
Vaccines based on Recombinant Proteins and Adjuvant Systems: GSK's malaria vaccine candidate as a case study. CMC Forum Vienna May 25-27 Vaccine workshop M.-C. Uwamwezi, Senior scientist Regulatory Affairs,
More informationThe revised European Directive 2010/63/EU: a guide for UK institutions
The revised European Directive 2010/63/EU: November 2010 Process of revision The new European Directive 2010/63/EU (to replace EU 86/609) was finalised and came into force across the EU in November 2010.
More informationDevelopment of non-substantially manipulated cell-based ATMPs 1 : flexibility introduced via the application of the risk-based approach
3 July 2017 EMA/CAT/216556/2017 Inspections, Human Medicines, Pharmacovigilance and Committees Division Development of non-substantially manipulated cell-based ATMPs 1 : flexibility introduced via the
More informationICH Q8/Q8(R)
Pharmaceutical Quality for the 21 st Century Temple University May 06, 2008 Joseph Famulare, Deputy Director FDA CDER Office of Compliance CDER Office of Compliance and the Critical Path Initiative Since
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE NON-CLINICAL DEVELOPMENT OF FIXED COMBINATIONS OF MEDICINAL PRODUCTS
European Medicines Agency London, 24 January 2008 Doc. Ref. EMEA/CHMP/SWP/258498/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE NON-CLINICAL DEVELOPMENT OF FIXED COMBINATIONS
More informationConsideration of Alternatives to the Use of Live Animals For Research and Teaching
Division of Laboratory Animal Resources Consideration of Alternatives to the Use of Live Animals For Research and Teaching From the ETSU Animal Study Protocol form: The search for alternatives refers to
More informationComparative Study of Regulatory Requirements for Biologics Filing in United States and European Union
Comparative Study of Regulatory Requirements for Biologics Filing in United States and European Union Mr. Shashi Kumar Yadav Assistant Professor Sri Indu Institute of Pharmacy Hyderabad Outline Introduction
More informationOVERVIEW OF DRUG REGISTRATION REQUIREMENTS FOR PHARMACEUTICALS IN EMERGING MARKET
Badjatya et al Journal of Drug Delivery & Therapeutics; 2013, 3(2), 227-232 227 Available online at http://jddtonline.info REVIEW ARTICLE OVERVIEW OF DRUG REGISTRATION REQUIREMENTS FOR PHARMACEUTICALS
More informationG R O U P E M E N T D I N T E R E T S C I E N T I F I Q U E
G R O U P E M E N T D I N T E R E T S C I E N T I F I Q U E Plateforme française pour le développement des méthodes alternatives en expérimentation animale RAPPORT A MADAME LA MINISTRE DE L ENSEIGNEMENT
More informationCategories of invasiveness A precautionary approach
AATEX 14, Special Issue, 715-720 Proc. 6th World Congress on Alternatives & Animal Use in the Life Sciences August 21-25, 2007, Tokyo, Japan Categories of invasiveness A precautionary approach Gilly Griffin,
More informationReflection paper on the dissolution specification for generic solid oral immediate release products with systemic action
10 August 2017 EMA/CHMP/CVMP/QWP/336031/2017 Committee for Medicinal Products for Human use (CHMP) Committee for Medicinal Products for Veterinary use (CVMP) Quality Working Party (QWP) Reflection paper
More informationNanotechnology and Advanced Materials for more effective Healthcare
Nanotechnology and Advanced Materials for more effective Healthcare This challenge taps into the potential of nanotechnologies and advanced materials to enable more effective therapies and diagnostics
More informationQuality Implementation Working Group on Q8, Q9 and Q10 Questions & Answers
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE Quality Implementation Working Group on Q8, Q9 and Q10 & Current version dated June
More informationExamples of regulatory expectations for analytical characterization and testing
Examples of regulatory expectations for analytical characterization and testing AT Europe 2016, 18 March 2016 Vicki Venizelos Quality RA B.V. Leiden, the Netherlands Overview What are the regulatory expectations?
More informationmopv & bopv: Licensing, Clinical Trials, and Strategies Manufacturer's Meeting, Geneva, 30 October 2008
mopv & bopv: Licensing, Clinical Trials, and Strategies Manufacturer's Meeting, Geneva, 30 October 2008 Research and Product Development Team, Polio Eradication Initiative, WHO, Geneva Focus of GPEI Research
More informationAdoption by CHMP for release for 3-month public consultation 18 November End of consultation (deadline for comments) 28 February 2011
18 October 2012 EMA/651649/2010 Committee for Medicinal Products for Human Use Reflection paper on considerations given to designation of a single stereo isomeric form (enantiomer), a complex, a derivative,
More informationA case study of development, validation, and acceptance of a non-animal method for assessing human vaccine potency
Available online at www.sciencedirect.com Procedia in Vaccinology 5 (2011) 184 191 NICEATM-ICCVAM # International Workshop on Alternative Methods to Reduce, Refine, and Replace the Use of Animals in Vaccine
More information3.1 Considerations for establishing lot release procedures by the NRA/NCL Encouragement of networking and work-sharing 53
Annex 2 Guidelines for independent lot release of vaccines by regulatory authorities Abbreviations 49 1. Introduction 49 1.1 Scope 50 2. Glossary 50 3. General considerations 51 3.1 Considerations for
More informationEUROPEAN INDUSTRIAL PHARMACISTS GROUP. Guidance on CPD for QUALIFIED PERSONS
EUROPEAN INDUSTRIAL PHARMACISTS GROUP Guidance on CPD for QUALIFIED PERSONS EIPG Guidance on CPD for QP Continuing Professional Development for Qualified Persons, Technical Directors and other Responsible
More informationBest Practices and Application of GMPs for Small Molecule Drugs in Early Development IQ Workshop, Feb 4-5, 2014, Washington, D.C.
Best Practices and Application of GMPs for Small Molecule Drugs in Early Development IQ Workshop, Feb 4-5, 2014, Washington, D.C. Manufacturing Breakout Session 1 Survey Results: Drug Product Manufacturing
More informationReplacement, Reduction and Refinement of Animal Testing in the Quality Control of Human Vaccines
Replacement, Reduction and Refinement of Animal Testing in the Quality Control of Human Vaccines Brief description of ongoing projects Marlies Halder December 2015 EUR 27646 Replacement, Reduction and
More informationPh. Eur. monographs and biosimilars
Ph. Eur. monographs and biosimilars Emmanuelle Charton, Ph. D. European Pharmacopoeia Department European Directorate for the Quality of Medicines & HealthCare 1 Place of the Ph. Eur. within the EU regulatory
More informationImproving animal welfare and reducing animal use for veterinary vaccine potency testing: state of the science and future directions
University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln Publications from USDA-ARS / UNL Faculty U.S. Department of Agriculture: Agricultural Research Service, Lincoln, Nebraska
More informationPharmacology. Chatchai Chinpaisal, Ph.D. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Silpakorn University.
Pharmacology Chatchai Chinpaisal, Ph.D. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Silpakorn University. 1 PHARMACODYNAMIC STUDIES A. Primary pharmacodynamics primary action in target
More informationTechnical guide for the ELABORATION AND USE OF MONOGRAPHS ON HUMAN PLASMA- DERIVED PRODUCTS
Technical guide for the ELABORATION AND USE OF MONOGRAPHS ON HUMAN PLASMA- DERIVED PRODUCTS European Pharmacopoeia EDQM 2015 Technical guide for the ELABORATION AND USE OF MONOGRAPHS AND GENERAL CHAPTERS
More informationChapter 12. Reduction and Refinement
Chapter 12 Reduction and Refinement Reduction and Refinement Introduction 12.1 In the previous chapter we discussed the opportunities and current limitations of the first of Russell and Burch s Three
More informationThe European partnership for alternative approaches to animal testing
AATEX 14, Special Issue, 769-773 Proc. 6th World Congress on Alternatives & Animal Use in the Life Sciences August 21-25, 2007, Tokyo, Japan The European partnership for alternative approaches to animal
More informationPRECLINICAL DRUG DISCOVERY AND DEVELOPMENT BIOBOOT CAMP 2016
PRECLINICAL DRUG DISCOVERY AND DEVELOPMENT BIOBOOT CAMP 2016 1 FROM DISCOVERY TO COMMERCIALIZATION At least 10 years on average Average spend of $1.4B Less than 12% of drugs entering Phase I are approved
More informationICH Quality Implementation Working Group POINTS TO CONSIDER
ICH Quality Implementation Working Group POINTS TO CONSIDER ICH-Endorsed Guide for ICH Q8/Q9/Q10 Implementation Document date: 16 June 2011 International Conference on Harmonisation of Technical Requirements
More informationComparative Analysis of the Revised Directive 2010/63/EU for the Protection of Laboratory Animals with its Predecessor 86/609/EEC a t 4 Report
Comparative Analysis of the Revised Directive 2010/63/EU for the Protection of Laboratory Animals with its Predecessor 86/609/EEC a t 4 Report Thomas Hartung Johns Hopkins University, CAAT, US, and CAAT-Europe,
More informationFDA S GUIDANCE FOR INDUSTRY ANDAS: STABILITY TESTING OF DRUG SUBSTANCES AND PRODUCTS
FDA S GUIDANCE FOR INDUSTRY ANDAS: STABILITY TESTING OF DRUG SUBSTANCES AND PRODUCTS 02-December-2014 San Diego, CA Kim Huynh-Ba Executive Director PHARMALYTIK Kim.huynhba@pharmalytik.com Overview Stability
More informationCurrent Regulatory Thinking The Draft Reflection Paper On Intravenous Liposomal Product Quality Issues
Current Regulatory Thinking The Draft Reflection Paper On Intravenous Liposomal Product Quality Issues Dr. René Thürmer BfArM - and dmedical ldevices AGAH Workshop on Liposomal Formulations Bonn / 21.
More informationJustification of Specifications (JOS): What Product and Process Development was all About. Christopher A Bravery
Justification of Specifications (JOS): What Product and Process Development was all About Christopher A Bravery cbravery@advbiols.com 1 The Importance of Characterisation 2 http://www.advbiols.com/documents/importance
More informationGuidelines on the nonclinical evaluation of vaccine adjuvants and adjuvanted vaccines
Annex 2 Guidelines on the nonclinical evaluation of vaccine adjuvants and adjuvanted vaccines Introduction 61 Background 62 Scope 62 General considerations 63 Terminology 65 Part A. Manufacturing and quality
More informationCOMMITTEE FOR THE MEDICINAL PRODUCT FOR HUMAN USE (CHMP)
European Medicines Agency London, 26 April 2007 Doc. Ref. EMEA/CHMP/GTWP/367513/2006 COMMITTEE FOR THE MEDICINAL PRODUCT FOR HUMAN USE (CHMP) CONCEPT PAPER ON The development of a Guideline on clinical
More informationNew Biological Reference Materials in 2015 Updated January 2016
New Biological Reference Materials in 2015 Updated January 2016 Part Number Part Description/ Intended use INTERNATIONAL STANDARDS AND REFERENCE PREPARATIONS 13/172 Lupus Anticoagulant (1st International
More informationBeth Hutchins, PhD PhRMA ICH Gene Therapy Discussion Group
ICH Considerations on General Principles to Address the Risk of Inadvertent Germline Integration of Gene Therapy Vectors and Current Topics on Gene Therapy in USA Beth Hutchins, PhD PhRMA ICH Gene Therapy
More informationThe Increasing Use of Genetically-altered Animals Threatens the Credibility of Directive 2010/63/EU
ATLA 41, 199 203, 2013 199 Editorial The Increasing Use of Genetically-altered Animals Threatens the Credibility of Directive 2010/63/EU Michael Balls The new EU Directive and the equivalent legislation
More informationWorkshop on Business Modeling for Sustainable Influenza Vaccine Manufacturing
Workshop on Business Modeling for Sustainable Influenza Vaccine Manufacturing Session 7: National regulatory authority s role in product commercialization, licensing and innovation of influenza vaccines
More informationEuropean Medicines Agency Evaluation of Medicines for Human Use
European Medicines Agency Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BWP/49348/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR BIOLOGICAL MEDICINAL
More informationCQAs for C> Products to Enable Comparability Assessment. Ben Thompson Snr Director, Biopharmaceutical CMC RA GlaxoSmithKline
CQAs for C> Products to Enable Comparability Assessment Ben Thompson Snr Director, Biopharmaceutical CMC RA GlaxoSmithKline Overview Demonstrate the value of defining CQAs early in product development
More informationBest Practices for the Use of International Standards in Vaccine Testing Dianna Wilkinson
Best Practices for the Use of International Standards in Vaccine Testing Dianna Wilkinson DCVMN Regional Training Workshop Hyderabad, 07-10 May, 2018 Biologicals substances which cannot be fully characterized
More informationBioengineering to reduce animal use and improve drug development
Bioengineering to reduce animal use and improve drug development Anthony Holmes PhD Programme Manager Technology Development NC3Rs Institute of Bioengineering Launch Event Queen Mary, University of London
More informationWork to be Done vs. Animal Welfare
Research Animal Facilities 14th Transgenic Technology Meeting, TT2017 Work to be Done vs. Animal Welfare Boris Jerchow, PhD MY EXPERIENCE Basic Research Transgenic Service AWO Facility Director ANIMAL
More informationThe Three Rs. Definitions, History, and Examples of the Three Rs
The Three Rs MARK J. PRESCOTT National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), United Kingdom Definitions, History, and Examples of the Three Rs The term the
More informationFDA Public Hearing: Approval Pathway for Biosimilar. Products. November 2-3, 2010
FDA Public Hearing: Approval Pathway for Biosimilar and Interchangeable Biological Products November 2-3, 2010 1 The Biotechnology Industry Organization Over 1,100 members, including biotechnology companies,
More informationNew Frontiers in the Quality of Medicines
New Frontiers in the Quality of Medicines Workshop European Biological Standardisation Programme (BSP) Moderators: Dr Roland Dobbelaer Dr John Purves EDQM International Conference 13-15 June 2007 Strasbourg,
More informationSafety Testing of Chinese Hamster Ovary (CHO) Cell Banks
Safety Testing of Chinese Hamster Ovary (CHO) Cell Banks Biosafety testing within the manufacturing process should be established in the early stages of drug development. We offer biosafety testing services
More informationWorkshop 3.3 Forum of national and international institutions funding
Workshop 3.3 Forum of national and international institutions funding ECVAM and its collaborative efforts to ensure a better co-ordination and funding of research, development and validation of alternative
More information